IP Library › Assignment 047727/0794

Patent Assignment

Reel/Frame 047727/0794

Assignment of Assignor's Interest

Recorded: 2018-12-10 Pages: 9

View PDF Order Certified Copy

Assignors

COGSWELL, JOHN P.

Executed: 2013-06-10

GOLDBERG, STACIE M.

Executed: 2013-06-18

GUPTA, ASHOK K.

Executed: 2013-06-10

JURE-KUNKEL, MARIA

Executed: 2013-06-19

WANG, XI-TAO

Executed: 2013-06-10

WIGGINTON, JON M.

Executed: 2013-07-17

Assignee

BRISTOL-MYERS SQUIBB COMPANY

RT. 206 & PROVINCE LINE ROAD, PRINCETON, NEW JERSEY, 08543-4000

Covered Properties (8)

Cancer Immunotherapy by Disrupting Pd-1/Pd-L1 Signaling

Patent: 10,316,090 →

Application: 16/006,365 →

Publication: US 2018/0273624

Cancer Immunotherapy by Disrupting Pd-1/Pd-L1 Signaling

Patent: 10,138,299 →

Application: 16/006,473 →

Publication: US 2018/0282413

Cancer Immunotherapy by Disrupting Pd-1/Pd-L1 Signaling

Patent: 10,323,092 →

Application: 16/006,493 →

Publication: US 2018/0282414

Cancer Immunotherapy by Disrupting Pd-1/Pd-L1 Signaling

Patent: 10,316,091 →

Application: 16/024,333 →

Publication: US 2018/0312590

Cancer Immunotherapy by Disrupting Pd-1/Pd-L1 Signaling

Patent: 10,308,714 →

Application: 16/024,340 →

Publication: US 2018/0319887

Cancer Immunotherapy by Disrupting Pd-1/Pd-L1 Signaling

Patent: 10,266,594 →

Application: 16/213,954 →

Publication: US 2019/0100589

Cancer Immunotherapy by Disrupting Pd-1/Pd-L1 Signaling

Patent: 10,266,595 →

Application: 16/213,960 →

Publication: US 2019/0092863

Cancer Immunotherapy by Disrupting Pd-1/Pd-L1 Signaling

Patent: 10,266,596 →

Application: 16/213,965 →

Publication: US 2019/0100590